SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                ---------------

                                    FORM 8-K
                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

         Date of Report (Date of earliest event reported): June 11, 2004

                               ------------------

                           DRAGON PHARMACEUTICAL INC.
               (Exact Name of Registrant as Specified in Charter)


             Florida                        0-27937             65-0142474
(State or Other Jurisdiction of    (Commission File Number)    (IRS Employer
         Incorporation)                                      Identification No.)


         1055 Hastings Street, Suite 1900                          V6E 2E9
           Vancouver, British Columbia                           (Zip Code)
      (Address of Principal Executive Offices)




       Registrant's telephone number, including area code: (604) 669-8817

                                       N/A
          (Former Name or Former Address, if Changed Since Last Report)

<PAGE>

Item 5.  Other Events and Regulation FD Disclosure

     On June 14, 2004, Dragon Pharmaceutical,  Inc. ("Dragon") announced that it
had executed a Share  Purchase  Agreement  with  Oriental  Wave Holding  Ltd., a
company  incorporated  under the laws of the British Virgin  Islands  ("Oriental
Wave") and the  shareholders  of Oriental  Wave dated June 11,  2004.  Under the
Share Purchase Agreement,  Dragon will purchase all of Oriental Wave's shares in
consideration  for the  issuance  of  shares  of  common  stock of  Dragon.  The
acquisition of Oriental Wave is subject to a number of conditions, including the
approval by Dragon's  shareholders  of the issuance of Dragon's shares of common
stock to the Oriental Wave shareholders.

     Oriental Wave is a private company and through its wholly-owned subsidiary,
Shanxi  Weiqida  Pharmaceutical  Co.,  Ltd.,  is  engaged in the  production  of
chemical   intermediates   and  active   pharmaceutical   ingredients   and  the
formulation,  marketing and sale of generic drugs.  Assuming the  acquisition is
completed, Oriental Wave will become a wholly-owned subsidiary of Dragon and the
current Oriental Wave shareholders will own approximately 68.35% of Dragon.

     A copy of the June 14, 2004 press release is attached as an exhibit.

Item 7. Financial Statements and Exhibits

        Exhibit No.    Exhibit Description
        ----------     -------------------
          10.16        Share Purchase Agreement Among Dragon Pharmaceutical,
                       Inc., Oriental Wave Holding  Ltd., and Yan-Lin Han,
                       Zhan Guo-Weng and Xue-Mei Liu.

           99.1        Press release announcing agreement with Oriental Wave


                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                       DRAGON PHARMACEUTICAL INC.


Date: June 21, 2004                   By:     /s/ Matthew Kavanagh
                                              ----------------------------------
                                       Name:  Matthew Kavanagh
                                       Title: Director of Finance and Compliance
                                             (Principal Financial and Accounting
                                              Officer)
[{"type": "8-K", "sequence": "1", "filename": "form8k06112004.txt", "description": "FORM 8-K RE MERGER WITH ORIENTAL WAVE", "secsgml_size_bytes": 3689}]
{"company-data": {"conformed-name": "DRAGON PHARMACEUTICALS INC", "cik": "0001075206", "assigned-sic": "2834", "irs-number": "650142474", "state-of-incorporation": "FL", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-27937", "film-number": "04872982"}, "business-address": {"street1": "543 GRANVILLE STREET SUITE 1200", "city": "VANCOUVER BC V6C 1X8", "state": "A1"}, "mail-address": {"street1": "543 GRANVILLE STREET SUITE 1200", "street2": "VANCOUVER BRITISH COLUMBIA CANADA V6C1X", "city": "VANCOUVER BRITISH CO"}}
SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                ---------------

                                    FORM 8-K
                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

         Date of Report (Date of earliest event reported): June 11, 2004

                               ------------------

                           DRAGON PHARMACEUTICAL INC.
               (Exact Name of Registrant as Specified in Charter)

             Florida                        0-27937             65-0142474
(State or Other Jurisdiction of    (Commission File Number)    (IRS Employer
         Incorporation)                                      Identification No.)

         1055 Hastings Street, Suite 1900                          V6E 2E9
           Vancouver, British Columbia                           (Zip Code)
      (Address of Principal Executive Offices)

       Registrant's telephone number, including area code: (604) 669-8817

                                       N/A
          (Former Name or Former Address, if Changed Since Last Report)
Item 5.  Other Events and Regulation FD Disclosure

     On June 14, 2004, Dragon Pharmaceutical,  Inc. ("Dragon") announced that it
had executed a Share  Purchase  Agreement  with  Oriental  Wave Holding  Ltd., a
company  incorporated  under the laws of the British Virgin  Islands  ("Oriental
Wave") and the  shareholders  of Oriental  Wave dated June 11,  2004.  Under the
Share Purchase Agreement,  Dragon will purchase all of Oriental Wave's shares in
consideration  for the  issuance  of  shares  of  common  stock of  Dragon.  The
acquisition of Oriental Wave is subject to a number of conditions, including the
approval by Dragon's  shareholders  of the issuance of Dragon's shares of common
stock to the Oriental Wave shareholders.

     Oriental Wave is a private company and through its wholly-owned subsidiary,
Shanxi  Weiqida  Pharmaceutical  Co.,  Ltd.,  is  engaged in the  production  of
chemical   intermediates   and  active   pharmaceutical   ingredients   and  the
formulation,  marketing and sale of generic drugs.  Assuming the  acquisition is
completed, Oriental Wave will become a wholly-owned subsidiary of Dragon and the
current Oriental Wave shareholders will own approximately 68.35% of Dragon.

     A copy of the June 14, 2004 press release is attached as an exhibit.

Item 7. Financial Statements and Exhibits

        Exhibit No.    Exhibit Description
        ----------     -------------------
          10.16        Share Purchase Agreement Among Dragon Pharmaceutical,
                       Inc., Oriental Wave Holding  Ltd., and Yan-Lin Han,
                       Zhan Guo-Weng and Xue-Mei Liu.

           99.1        Press release announcing agreement with Oriental Wave

                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                       DRAGON PHARMACEUTICAL INC.

Date: June 21, 2004                   By:     /s/ Matthew Kavanagh
                                              ----------------------------------
                                       Name:  Matthew Kavanagh
                                       Title: Director of Finance and Compliance
                                             (Principal Financial and Accounting
                                              Officer)